微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-09-30 | 21.1% | -18.71% | -11.64% | 135/159 | 50.44% | 迪哲医药 | 99.22% | 行业排名> |
| 2026-06-30 | 23.88% | -20.8% | 11.98% | 126/159 | 48.66% | 海创药业 | 97.34% | 行业排名> |
| 2026-03-31 | 21.33% | -39.7% | -9.7% | 137/159 | 50.28% | 海创药业 | 99.82% | 行业排名> |
| 2025-12-31 | 23.62% | -14.9% | -9.01% | 130/159 | 50.37% | 海创药业 | 98.62% | 行业排名> |
| 2025-09-30 | 25.96% | -3.77% | -13.91% | 125/159 | -2.13% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 30.15% | 16.82% | -14.75% | 118/159 | 15.05% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 35.37% | 39.24% | 27.43% | 101/159 | 31.79% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 27.76% | 4.19% | 2.89% | 124/159 | 51.61% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 26.98% | 3.24% | 4.52% | 122/159 | 22.43% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 25.81% | 6.31% | 1.61% | 125/159 | 32.96% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 25.4% | 14.22% | -4.65% | 126/159 | 51.47% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 26.64% | 16.75% | 1.95% | 126/159 | 51.31% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 26.13% | 21.73% | 7.62% | 126/159 | 32.31% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 24.28% | 12.34% | 9.17% | 130/159 | 38.22% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 22.24% | -9.94% | -2.54% | 128/159 | 52.66% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 22.82% | -19.17% | 6.31% | 137/159 | 53.51% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 21.46% | -30.36% | -0.68% | 131/159 | 5.67% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 21.61% | -35.63% | -12.48% | 135/159 | 20.91% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 24.69% | -26.4% | -12.53% | 124/159 | 54.06% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 28.23% | -16.9% | -8.41% | 130/159 | 54.9% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 30.82% | -15.73% | -8.2% | 112/159 | 46.49% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 33.58% | -11.12% | 0.08% | 115/159 | 46.97% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 33.55% | 2% | -1.24% | 97/159 | 53.79% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 33.97% | -2.94% | -7.13% | 120/159 | -147.51% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 36.58% | 2% | -3.17% | 96/159 | 56.06% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 37.78% | 10.65% | 7.94% | 100/159 | 53.85% | 微芯生物 | 95.14% | 行业排名> |
| 2019-12-31 | 35% | 5.88% | 2.52% | 109/159 | -1232.76% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-06-30 | 34.14% | 2% | 3.28% | 93/159 | 54.88% | 微芯生物 | 95.81% | 行业排名> |
| 2018-12-31 | 33.05% | 9.31% | 9.31% | 106/159 | -210.26% | 微芯生物 | 96.09% | 行业排名> |
| 2017-12-31 | 30.24% | -8.59% | -8.59% | 103/159 | 52.25% | 微芯生物 | 96.11% | 行业排名> |
| 2016-12-31 | 33.08% | 2% | 2% | 81/159 | 48.17% | 微芯生物 | 95.5% | 行业排名> |